Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma

Clinical Cancer Research

Volumn 16, Issue 23, 2010, Pages 5692-5702

  Dubrovska, Anna ^a   Elliott, Jimmy ^b   Salamone, Richard J ^b   Kim, Sungeun ^b,f   Aimone, Lindsey J ^b   Walker, John R ^b   Watson, James ^b   Sauveur Michel, Maira ^c   Garcia Echeverria, Carlos ^c,e   Cho, Charles Y ^b   Reddy, Venkateshwar A ^a,b,d   Schultz, Peter G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Sanofi US   (United States)

^e SANOFI   (France)

^f AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CD133 ANTIGEN; DOCETAXEL; HERMES ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG INHIBITION; DRUG MECHANISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; GLYCOPROTEINS; HUMANS; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PEPTIDES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; QUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650312347     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1601     Document Type: Article

References (47)

1. Grubb RL, Kibel AS. Prostate cancer: screening, diagnosis and management in 2007. Mol Med 2007 ;104:408-12.
2. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature 2004;432:396-401.
4. Tang DG, Patrawala L, Calhoun T, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14.
5. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer initiating cells. Cancer Res 2008;68:9703-11.
6. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression. J Cell Sci 2001;114:3865-72.
7. Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006;33:201-10.
8. Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/AKT/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009;106:268-73.
9. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/AKT pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4:226-35.
10. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/AKT/beta-catenin signaling. PLoS Biol 2009;6:e1000121.
11. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475-82. (Pubitemid 44050144)
12. + primary colon cancer cells. Carcinogenesis 2010;31:1376-80.
13. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825-31.
14. Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56.
15. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-50.
16. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63.
17. He XC, Yin T, Grindley JC, et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007;39:189-98.
18. Wang S, Garcia AJ, Wu M, et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 2006;103:1480-5. (Pubitemid 43191191)
19. Chin YR, Toker A. Function of AKT/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 2009;21:470-6.
20. Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2008;104:16158-63.
21. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.
22. Richardson GD, Robson CN, Lang SH, et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2005;117:3539-45.
23. Wei C, Guomin W, Yujun L, et al. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 2007;6:763-8.
24. Miki J, Furusato B, Li H, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67:3153-61.
25. Li H, Chen X, Calhoun-Davis T, et al. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008;68:1820-5.
26. Goya M, Ishii G, Miyamoto S, et al. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 2006;66:1573-84.
27. Beer TM, Garzotto M, Henner WD, et al. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004;91:1425-7. (Pubitemid 39371954)
28. Stordal BK, Davey MW, Davey RA. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemother Pharmacol 2006;58:256-65.
29. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 2006;12:6565-72.
30. Sun X, Huang J, Homma T, et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009;29:1739-43.
31. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-98.
32. Liang Y, Zhong Z, Huang Y, et al. Stem-like cells are inducible by increasing genomic instability in cancer cells. J Biol Chem 2010;285:4931-40.
33. Conway A, Lindgren A, Galic Z, et al. A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors. Stem Cells 2009;27:18-28.
34. Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
35. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007;18:460-6.
36. McDonald SA, Graham TA, Schier S, et al. Stem cells and solid cancers. Virchows Arch 2009;455:1-13.
37. Ischenko I, Seeliger H, Schaffer M, et al. Cancer stem cells: how can we target them? Curr Med Chem 2008;15:3171-84.
38. Frei E III, Karon M, Levin RH, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965;26:642-56.
39. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-11.
40. Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mal Cancer Ther 2010;9:2582-92.
41. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15:4799-805.
42. Eyler CE, Foo W-C, LaFiura KM, et al. Brain cancer stem cells display preferential sensitivity to AKT inhibition. Stem Cells 2008;26:3027-36.
43. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4.
44. Dibble CC, Manning BD. A molecular link between AKT regulation and chemotherapeutic response. Cancer Cell 2009;16:178-80.
45. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9. (Pubitemid 28047054)
46. Schmidt EE, Ichimura K, Goike HM, et al. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 1999;58:1170-83.
47. Chen Z, Trotman L, Shaffer D, et al. Critical role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. Nature 2005;436:725-30.